Tel Aviv-based company seeks valuation of at least $3.5 billion to $4 billion, after coronavirus pandemic led to a boost of activity with firms seeking work from home solutions

Rehovot-based oncology company develops drugs to treat rare and aggressive cancers, files prospectus for New York offering

Calcalist: Firm makes non-invasive diagnostic devices for cardiovascular diseases and sleep disorders; funds will be used for marketing and product development

Calcalist: Israel-based firm that develops targeted therapies for cancer is planning an initial public offering of shares at company valuation of $400 million

Netanya-based firm streamlines software updates for global players, including Google, Amazon, Facebook

Globes: The Israeli firm's key product -- a delayed-release pill to treat advanced Parkinson's -- didn't demonstrate better performance over existing drugs

Calcalist: The Israel-based firm is seeking to raise some $100 million at a company valuation of $400 million to $500 million, two people familiar with the matter say

Calcalist: The Israeli firm that develops headsets to treat brain disorders by using magnetic stimulation is now dually listed in Tel Aviv and on the Nasdaq